Literature DB >> 6307140

Anti-interferon antibody increases rhinovirus isolation rates from nasal wash specimens containing interferon-alpha 2.

F G Hayden, J M Gwaltney.   

Abstract

Isolation of rhinoviruses from nasal secretions may be delayed or prevented by exogenously applied interferon which is carried over into nasal wash specimens. In studies of interferon-alpha 2 treated volunteers with experimental rhinovirus infection, we determined that incorporation of antiinterferon antibody into collection broth significantly increased isolation rates (84% increase) and the proportion of monolayers positive for CPE (155% increase), as compared to plain collection broth.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6307140     DOI: 10.1016/0166-3542(83)90016-5

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  5 in total

1.  Immune modulation by aspirin during experimental rhinovirus colds.

Authors:  J Hsia; G L Simon; N Higgins; A L Goldstein; F G Hayden
Journal:  Bull N Y Acad Med       Date:  1989-01

2.  Comparative susceptibilities of strain MRC-5 human embryonic lung fibroblast cells and the Cooney strain of human fetal tonsil cells for isolation of rhinoviruses from clinical specimens.

Authors:  F C Geist; F G Hayden
Journal:  J Clin Microbiol       Date:  1985-09       Impact factor: 5.948

3.  Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds.

Authors:  B M Farr; J M Gwaltney; K F Adams; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

4.  Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds.

Authors:  F G Hayden; D L Kaiser; J K Albrecht
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

Review 5.  Utility of animal and in vivo experimental infection of humans with rhinoviruses in the development of therapeutic agents for viral exacerbations of asthma and chronic obstructive pulmonary disease.

Authors:  Alfred M Del Vecchio; Patrick J Branigan; Elliot S Barnathan; Susan K Flavin; Philip E Silkoff; Ronald B Turner
Journal:  Pulm Pharmacol Ther       Date:  2014-11-13       Impact factor: 3.410

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.